A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma

Trial Profile

A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs DCVAC OvCa (Primary) ; Doxorubicin; Paclitaxel; Topotecan
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors SOTIO
  • Most Recent Events

    • 01 Dec 2016 This trial was completed in Poland (end date: 2016-08-02), according to European Clinical Trials Database.
    • 29 Nov 2016 Status changed from active, no longer recruiting to discontinued.
    • 21 Nov 2016 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top